Our investment group continues to be sought after for insight into the financial markets, most recently by Barron’s. In a recent inquiry, Ernie Cecilia, chief investment officer at Bryn Mawr Trust, shared with Barron’s why his team’s research led him to believe a company like Novartis (NVS) is a strong pick for clients’ portfolios. Despite currency pressures from the strong Swiss franc, Ernie points to the company’s demonstrated continued commitment to research and development. Its R&D potential, coupled with its strategic positioning to capitalize on changing demographics of emerging markets, is why Ernie and the Bryn Mawr Trust equity research group sees significant potential in this equity.
Click here to stay on The Bryn Mawr Trust Company’s website. If you choose to continue to the external site, please visit Barrons.com.